2026
2025
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low grarde gliomas.
Apfelbaum April, Morin E, et al. Nature Commun. 2025 July 31;16(1):7018.
Deep learning volumetrics reveals distinct clinical trajectories for pediatric low-grade gliomas under surveillance: A multicenter study.
Climent Pardo JC, et al. Neuroncol Advances. 2025 July 1;7(1):vdaf145.
Longitudinal risk prediction for pediatric glioma with temporal deep learning
Tak, et al. NEJM AI. 2025 May;2(5):10.1056/aioa2400703
Incidental Diffuse Midline Glioma, H3 K27-altered of the pons without significant coalterations
Yeo, et al. JCO Precis Oncol. 2025 June: 9:e2400944
Recurrent breakpoints in the BRD4 locus reduce toxicity associated with gene amplification
Wala, et al. Cell Genom. 2025 April 9; 5(4):100815.
Effective targeting of PDGFRA-altered-high-grade glioma with avapritinib
Mayr L, et al. Cancer Cell. 2025 April 14;43(4):740-756.
A compendium of amplification-related gain of sensitivity genes in human cancer.
Rendo V, et al. Nature Commun. 2025 Jan 27;16(1):1077.
2024
Pediatric neuro-oncology: Highlights of the last quarter-century.
Neoplasia. 2025 Jan: 59:101098.
FOXR2 targets LHX6+/DLX+ neural lineages to drive CNS neuroblastoma.
Cancer Res. 2024 Nov 4
Multimodal deep learning improves recurrence risk prediction in pediatric low-grade gliomas.
Neuro Oncol. 2024 Aug 30: noae173.
Genome-wide CRISPR-Cas9 knockout screens identify DNMTA1 as a druggable dependency in sonic hedgehog medulloblastoma.
Acta Neuropathol Commun. 2024 August 7;12(1):125.
Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer.
Nat Commun. 2024 July 11;15(1):5837.
Resistance, rebound, and recurrence growth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma Coalition
Neuro Oncol. 2024 Aug 5;26(8):1357-1366.
Noninvasive molecular subtyping of pediatric low-grade glioma with self-supervised transfer learning
Radiol Artif Intell. 2024 May;6(3):e230333.
Aberrant DNA repair reveals a vulnerability in histone H3.3-mutant brain tumors.
Nucleic Acids Res. 2024 Mar 21;52(5):2372-2388.
Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma
Mol Cell. 2024 Jan 18;84(2):261-276.e18.
2023
A road map for the treatment of pediatric diffuse midline glioma
Cancer Cell. 2023 Nov 20: S1535-6108(23)00393-8.
Pediatric low-grade glioma: State-of-the-art and ongoing challenges
Neuro Oncol. 2023 Nov 7; noad195.
Indoximod-based chemo-immunotherapy for pediatric brain tumors: a first-in-children phase 1 trial
Neuro Oncol. 2023 Sep 16; noad176.
The ‘LOGGIC’ of RNA-sequencing in enhancing diagnoses of pediatric low-grade gliomas
Neuro Oncol. 2023 Aug 2; noad142.
A pilot study omitting radiation in the treatment of children with newly diagnosed WNT-activated medulloblastoma.
Clin Cancer Res. 2023 July 27, CCR-23–348.
Genome-wide pooled CRISPR screening in neurospheres.
Nat Protocols. 2023 June 7.
Accurate diagnosis of pediatric brain cancers.
Nat Medicine. 2023 Mar 17.
Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment.
Neurooncol Advances. 2022 Dec 18;5(1):vdac182.
ALK amplification and rearrangements are recurrent targetable events in congenital and adult glioblastoma.
Clin Cancer Research. 2023 Feb 13; CCR-21-3521.
Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era.
Neoplasia. 2023 Feb; 36:100857.
K27M in canonical and noncanonical H3 variants occurs in distinct oligodendroglial cell lineages in brain midbrain gliomas
Nat Genetics. 2022 Dec; 54(12); 1865-1880
2022
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Eur J Cancer. 2022 Oct 14;177:120-142.
Molecular genetics of paediatric brain tumours and opportunities for precision medicine – a focus on infant brain tumors.
Curr Opin Neurol. 2022 Oct 5.
BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma
Neuro Oncol. 2022 Aug 17; noac199.
Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma
Nat Commun Aug 16;13(1):4814.
FOXR2 is an epigenetically regulated pan-cancer oncogene that activates ETS transcriptional circuits
Cancer Research 2022 July 8.
Featured in the Broad Blog here.
Structural variants shape driver combinations and outcomes in pediatric high-grade glioma
Nat Cancer 2022 July 4.
Featured in the DFCI Blog here.
Pediatric pineoblastoma: A pooled outcome study of North American and Australian therapeutic data
Neurooncol Adv 2022 April 14; 4(1):vdac056.
PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation
Nature Commun 2022 Feb 1; 13(1):604.
Featured on this Broad News Update.
Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF and Urine.
Neuro Oncol 2022 Jan 4
Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry
Neuro Oncol 2021 Oct 20
Molecular alterations in pediatric low-grade gliomas that led to death
J Neuropathol Exp Neurol 2021 Nov 19; 80(11):1052-1059
The challenges in treating embryonal tumors with multilayered rosettes (ETMR) and other infant brain tumors
Neuro Oncol. 2022 Jan 5; 24(1):138-140
Characteristics of patients greater than 10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry
Neuro Oncol. 2022 Jan 5;24(1):141-152
2021
A first-generation pediatric cancer dependency map
K. Nat Genet. 2021 Mar 22
Bromodomain and extra-terminal inhibitors. A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children – ACCELERATE
Eur J Cancer. 2021 Mar; 146:115-124.
Outcomes after first relapse of childhood intracranial ependymoma
Pediatr Blood Cancer. 2021 Feb 9. e28930.
2020
Advances in the classification and treatment of pediatric brain tumors
Curr Opin Pediatr. 2020 Dec 4.
Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis
Cell (2020); S0092-8674(20)31529-4
CloneSifter: enrichment of rare clones from heterogenous cell populations
BMC Biology (2020); Nov 24;18(1):177.
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
Nature Commun (2020); Sept 21;11(1):4748.
Sex differences in oncogenic mutational processes
Nature Commun (2020); Aug 28;11(1):4330.
Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma
J Neuro-Onc (2020); Sept;149(2):253-262.
Mechanisms and therapeutic implications of hypermutation in gliomas
Nature (2020) Pub online 15 April 2020.
The “Risk” in Pediatric Low-Grade Glioma
Cancer Cell (2020); Apr 13;37(4): 424-425.
Analyses of non-coding somatic drivers in 2,658 cancer whole genomes
Nature (2020); 578 (7793): 102-111.
Pan-cancer Analysis of whole genomes
Nature (2020); 578 (7793): 82-93.
Pathway and Network Analysis of more than 2500 whole cancer genomes
Nature Commun (2020); 11(1):729. Published 2020 Feb 5.
Combined burden and functional impact tests for cancer driver discovery using DriverPower
Nature Commun (2020); 11(1):734. Published 2020 Feb 5.
Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway
Cancer Cell (2020) Jan 13; 37(1):104-122.e12.
2019
Neuro Oncology. Feb 2019/21(8):968-980.
Annual Review of Genetics. Dec 2019/53;483-503.
Neuro Oncology. Feb 2019/21(2);143-145.
Nature Communications. August 2019/ 10(1):3731.
Current Opinions in Pediatrics. Feb 2019/31 (1);21-27.
Nature. 2019 Nov/575(7783);545-550.
2018
Journal of Neuro-Oncology. 2018 Nov; 140(2):269-279.
Cell Chem Biol. 2018 Jan; 25(1):88-99.
J Neurooncology. April 2018/137(2):269-278.
2017
Acta Neuropathology. 2017; 134(4):667-669.
Neuro Oncol. 2017 Jun; 19(6):774-785.
2016
Nature Genetics. 2016 Mar;48(3):273-82.
2015
Pediatr Blood Cancer. 2015 Jan;62(1):3-4.
2014
J Neurooncol. 2014 Aug;119(1):7-15.
Pediatr Blood Cancer. 2014 61(4):636-42.
J. Neuroscience. 2014 Jun; 34(25):8507-18.
Biochem Biophys Acta. 2014 1845(2) 294-307.
Cancer Cell. 2014 Mar 17;25(3):393-405.
Sci Transl Med. 2012 4(148) 148ra117.
Pediatr Blood Cancer. 2014 Sep;61(9):1598-602.
ACS Chem Biol. 2014 9(3):831-7.
J Clin Oncol. 2014 Aug 4. pii: JCO.2013.51.1766.
J Neurosurg Pediatr. Oct;14(4):356-64..
Am Soc Clin Oncol Educ Book. 2014:e436-40.
Proc Natl Acad Sci USA. 2014 Jul: 111(30):11121-6.
Nat Genet. 2014 Feb;46(2):161-5.
PNAS. 2014 Nov 11;111(45):E4869-77.
2013
Nat Med. 2013 Nov 19(11):1518-23.
Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1611-6.
International Cancer Genome Consortium PedBrain Tumor Project. Nat Genet. 2013 Aug;45(8):927-32. doi: 10.1038/ng.2682. Epub 2013 Jun 30. PMID:23817572.
Nat Genet. 2013 Aug: 45(8):927-32.
Proc Natl Acad Sci USA. 2013 May 14;110(20):8188-93. PMID:23633565.
Cancer Res. 2013 Apr 15;73(8):2574-86.
Science. 2013 Jul 19; 341(6143). PMID:1238303.
Nat Biotechnol. 2013 Jul; 31(7):630-7. PMID:23811600.
Sci Rep. 2013 Oct 4;3:2859. .
Sci Transl Med. 2013 Sep 4;5(201):201ra119.
Brain Pathol. 2013 Sep;23(5):565-73. doi: 10.1111/bpa.12043. Epub 2013 Mar 18. PMID:23438035.
2012
Blood Cancer. 2012 Dec 15;59(7):1155-7. doi: 10.1002/pbc.24315. Epub 2012 Sep 19. PMID:2997201.
Cancer Cell. 2012 Nov 13;22(5):668-82.
Nature. 2012 Mar 28;483(7391):570-5.
Nat Rev Neurosci. 2012 Dec;13(12):819-31. PMID:23165259.
2011
Cancer Cell. 2011 Mar 8;19(3):359-71.
Neuron. 2011 Mar 10;69(5):906-17.
